TriangleDISEASE & TREATMENT SETTING
Krazati: metastatic Non-small cell lung cancer with KRAS stated without a specific alteration after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Broader topic: Non-Small Cell Lung Cancer
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- KRAS
- alteration
- stated without a specific alteration
- status
- present
- prior therapy
- class
- who have received at least one prior systemic therapy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Krazati (adagrasib) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
- source wording
- Adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Study evidence for this setting
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice